Literature DB >> 8374870

Lymphatic flow in carcinoma of the distal bile duct based on a clinicopathologic study.

M Kayahara1, T Nagakawa, K Ueno, T Ohta, T Takeda, I Miyazaki.   

Abstract

BACKGROUND: Nodal status is one of the most important prognostic factors for distal bile duct cancer. The pattern of lymphatic spread of distal bile duct cancer was analyzed by determining the frequency of involvement of various lymph nodes.
MATERIALS AND METHODS: From 1973 to 1991, 29 patients with distal bile duct cancer underwent pancreaticoduodenectomy at Kanazawa University Hospital. A precise evaluation of their nodal involvement and the relationship among the lymph nodes was determined by histopathologic examination.
RESULTS: Twenty of the 29 (68.9%) patients had nodal involvement. The lymph nodes with a high metastatic rate were those around the lower portion of the hepatoduodenal ligament (number 12abp2), the superior posterior pancreaticoduodenal lymph nodes (number 13a), and the superior mesenteric artery (number 14) (12abp2, 24.1%; 13a, 51.7%; 14, 34.5%). At least one para-aortic lymph node was involved with cancer in two (6.9%) patients. All of the patients except one who had one or more positive number 14 lymph nodes also had positive number 12abp2 or 13a lymph nodes.
CONCLUSIONS: Lymph nodes number 12abp2 and 13a are important in lymphatic metastasis to superior mesenteric lymph node for distal bile duct cancer. Nodal dissection around the superior mesenteric artery should be performed in all patients except those without pancreatic invasion.

Entities:  

Mesh:

Year:  1993        PMID: 8374870     DOI: 10.1002/1097-0142(19931001)72:7<2112::aid-cncr2820720709>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors:  Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal:  J Gastrointest Oncol       Date:  2014-06

2.  Solitary recurrence of hilar cholangiocarcinoma in a mediastinal lymph node two years after curative resection.

Authors:  Yuichiro Ito; Yoshitsugu Tajima; Fumihiko Fujita; Ryuji Tsutsumi; Tamotsu Kuroki; Takashi Kanematsu
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

3.  The Likely Sites of Nodal Metastasis Differs According to the Tumor Extent in Distal Bile Duct Cancer.

Authors:  Yuichiro Kato; Shinichiro Takahashi; Naoto Gotohda; Masaru Konishi
Journal:  J Gastrointest Surg       Date:  2016-06-02       Impact factor: 3.452

4.  [Carcinomas of the distal bile duct].

Authors:  M Bahra; J M Langrehr; P Neuhaus
Journal:  Chirurg       Date:  2006-04       Impact factor: 0.955

5.  Pathological aspects of cholangiocarcinoma.

Authors:  I Esposito; P Schirmacher
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

6.  Predictors of survival in periampullary cancers following pancreaticoduodenectomy.

Authors:  Ioannis Hatzaras; Nathaniel George; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2010-01-28       Impact factor: 5.344

7.  Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer.

Authors:  Luciana Caravatta; Giuseppina Sallustio; Fabio Pacelli; Gilbert D A Padula; Francesco Deodato; Gabriella Macchia; Mariangela Massaccesi; Vincenzo Picardi; Savino Cilla; Alfonso Marinelli; Numa Cellini; Vincenzo Valentini; Alessio G Morganti
Journal:  Radiat Oncol       Date:  2012-06-12       Impact factor: 3.481

8.  Preoperative diagnosis of an asymptomatic cancer restricted to the cystic duct.

Authors:  Shuji Komori; Juji Tsuchiya; Iwao Kumazawa; Hajime Kawagoe; Kimitoshi Nishio; Yuki Misao
Journal:  Int J Surg Case Rep       Date:  2014-04-30

9.  Cystic duct cancer: Should it be deemed as a type of gallbladder cancer?

Authors:  Tu-Nan Yu; Ying-Ying Mao; Fang-Qiang Wei; Hui Liu
Journal:  World J Gastroenterol       Date:  2019-11-28       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.